<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-1430BCS1/a5321a1c-2bf2-4f2a-8dc0-0293a568cffe/HTML"><dcterms:extent>26 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-1430BCS1/c3f9b54a-3360-41a8-a557-4851aaa2cfd9/PDF"><dcterms:extent>345 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-1430BCS1/995c054b-7e9d-40e8-ab3a-788e33882439/TEXT"><dcterms:extent>22 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="2005-2025"><edm:begin xml:lang="en">2005</edm:begin><edm:end xml:lang="en">2025</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-1430BCS1"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/URN:NBN:SI:spr-8ER5ZBJN" /><dcterms:issued>2006</dcterms:issued><dc:creator>Pečar, Slavko</dc:creator><dc:creator>Perdih, Andrej</dc:creator><dc:format xml:lang="sl">številka:1</dc:format><dc:format xml:lang="sl">letnik:57</dc:format><dc:format xml:lang="sl">6 strani</dc:format><dc:format xml:lang="sl">str. 24-29</dc:format><dc:identifier>ISSN:0014-8229</dc:identifier><dc:identifier>COBISSID:1912945</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-1430BCS1</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Slovensko farmacevtsko društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Farmacevtski vestnik</dcterms:isPartOf><dc:subject xml:lang="sl">antioksidanti</dc:subject><dc:subject xml:lang="en">antioxidant</dc:subject><dc:subject xml:lang="en">drug</dc:subject><dc:subject xml:lang="sl">katalitični antioksidanti</dc:subject><dc:subject xml:lang="sl">metaloporfirini</dc:subject><dc:subject xml:lang="sl">reaktivne kisikove zmesi</dc:subject><dc:subject xml:lang="sl">saleni</dc:subject><dc:subject xml:lang="sl">superoksid dismutaza</dc:subject><dc:subject xml:lang="sl">zdravila</dc:subject><dcterms:temporal rdf:resource="2005-2025" /><dc:title xml:lang="sl">Katalitični antioksidanti kot nove zdravilne učinkovine|</dc:title><dc:description xml:lang="sl">Several pathological states involve the overproduction of reactive oxygen species (ROS). Manganese-containing compounds that mimic the dismutation reaction catalyzed by superoxide dismutase (SOD) disclose a novel class of potential scavengers of reactive oxygen species. These catalytic antioxidants represented by manganese-containing active agents are SOD mimetics divided into three groups by their in vitro selectivity towards the scavenging of superoxide free-radical. The class of selective catalytic antioxidants includes macrocyclics, whereas the non-selective catalytic antioxidants comprise salens and metalloporphyrins. Cardiovascular, neurodegenerative and inflammatory lung disorders are all potential targets for the future catalyticantioxidant therapy presented herein</dc:description><dc:description xml:lang="sl">Veliko bolezenskih stanj je povezanih s prekomernim nastajanjem reaktivnih kisikovih zvrsti (ROS). Z manganovimi spojinami, ki oponaoajo reakcijo dismutacije, ki jo katalizira encim superoksid dismutaza (SOD), se odpira moanost nevtralizacije reaktivnosti ROS. Ti katalitioeni antioksidanti, ki so manganove ione vsebujooee uoeinkovine, so mimetiki encima SOD. Razlikujejo se po in vitro selektivnosti odstranjevanja superoksidnega radikala. Najbolj selektivni so makrociklioeni mimetiki SOD, manj selektivni pa saleni in metaloporfirini. Predstavljene uoeinkovine so uoeinkovite pri zdravljenju kardiovaskularnih, nevrodegenerativnih in respiratornih boleznih, pri vnetnih procesih in pri modulaciji boleoeine ter predstavljajo pomemben poskus zaoeetka zdravljenja z uporabo katalitioenih antioksidantov</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-1430BCS1"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-1430BCS1" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-1430BCS1/c3f9b54a-3360-41a8-a557-4851aaa2cfd9/PDF" /><edm:rights rdf:resource="http://rightsstatements.org/vocab/InC/1.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko farmacevtsko društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-1430BCS1/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-1430BCS1" /></ore:Aggregation></rdf:RDF>